HRP20240088T1 - Mutageneza usmjerena na mjesto protutijela trem-1 za smanjenje viskoziteta - Google Patents
Mutageneza usmjerena na mjesto protutijela trem-1 za smanjenje viskoziteta Download PDFInfo
- Publication number
- HRP20240088T1 HRP20240088T1 HRP20240088TT HRP20240088T HRP20240088T1 HR P20240088 T1 HRP20240088 T1 HR P20240088T1 HR P20240088T T HRP20240088T T HR P20240088TT HR P20240088 T HRP20240088 T HR P20240088T HR P20240088 T1 HRP20240088 T1 HR P20240088T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- heavy chain
- variable region
- antibody
- light chain
- Prior art date
Links
- 230000003247 decreasing effect Effects 0.000 title 1
- 238000002741 site-directed mutagenesis Methods 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000018368 Triggering Receptor Expressed on Myeloid Cells-1 Human genes 0.000 claims 1
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (11)
1. Protutijelo koje je sposobno za vezanje na TREM-1 i za njegovo blokiranje, naznačeno time, da obuhvaća:
(i) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 4;
(ii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 5;
(iii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 6;
(iv) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 7;
(v) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 8;
(vi) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 9;
(vii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 10;
(viii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i laki lanac koji sadržava SEQ ID NO: 14;
(ix) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 11 i laki lanac koji sadržava SEQ ID NO: 3;
(x) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 12 i laki lanac koji sadržava SEQ ID NO: 3;
(xi) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 13 i laki lanac koji sadržava SEQ ID NO: 3;
(xii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 15 i laki lanac koji sadržava SEQ ID NO: 5; ili
(xiii) teški lanac koji sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 16 i laki lanac koji sadržava SEQ ID NO: 14;
pri čemu teški lanac sadrži IgG4 konstantnu regiju.
2. Protutijelo prema patentnom zahtjevu 1, naznačeno time, da teški lanac sadržava varijabilnu regiju teškog lanca od SEQ ID NO: 2 i pritom laki lanac sadržava SEQ ID NO: 5.
3. Farmaceutski pripravak, naznačen time, da sadrži protutijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i farmaceutski prihvatljiv nosač.
4. Prokariotska ili eukariotska stanica, naznačena time, da rekombinantno eksprimira protutijelo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2.
5. Postupak za proizvodnju protutijela prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, da obuhvaća rekombinantnu ekspresiju protutijela u prokariotskoj ili eukariotskoj stanici.
6. Protutijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, ili farmaceutski pripravak prema patentnom zahtjevu 3, naznačeni time, da su za uporabu kao lijek za pojedinca kojemu je on potreban.
7. Protutijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, ili farmaceutski pripravak prema patentnom zahtjevu 3, naznačeni time, da su za uporabu u liječenju upalne bolesti ili autoimune bolesti kod pojedinca kojemu je to potrebno.
8. Protutijelo ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 7, naznačeni time, da se upalna bolest ili autoimuna bolest bira iz skupine koju čine:
upalna bolest crijeva, Crohnova bolest, ulcerativni kolitis, sindrom iritabilnih crijeva, reumatoidni artritis, psorijaza, psorijatički artritis, sistemski eritematozni lupus, lupus nefritis, dijabetes tipa I, Graveova bolest, multipla skleroza, autoimuni miokarditis, Kawasaki bolest, bolest koronarnih arterija, kronična opstrukcijska plućna bolest, intersticijska plućna bolest, autoimuni tiroiditis, skleroderma, sistemska skleroza, osteoartritis, atopijski dermatitis, vitiligo, bolest usadak protiv domaćina, Sjögrensov sindrom, autoimuni nefritis, Goodpastureov sindrom, kronična upalna demijelinizacijska polineuropatija, alergija, astma i ostale autoimune bolesti koje su rezultat akutne ili kronične upale.
9. Protutijelo ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se protutijelo ili farmaceutski pripravak primjenjuju parenteralno.
10. Protutijelo ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se protutijelo ili farmaceutski pripravak primjenjuju profilaktički.
11. Protutijelo ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 10, naznačeni time, da pojedinac je čovjek.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14177547.8A EP2975056A1 (en) | 2014-07-17 | 2014-07-17 | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
EP14194893.5A EP3026061A1 (en) | 2014-11-26 | 2014-11-26 | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
EP15738925.5A EP3172232B1 (en) | 2014-07-17 | 2015-07-17 | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
PCT/EP2015/066501 WO2016009086A1 (en) | 2014-07-17 | 2015-07-17 | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240088T1 true HRP20240088T1 (hr) | 2024-04-12 |
Family
ID=53673951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240088TT HRP20240088T1 (hr) | 2014-07-17 | 2015-07-17 | Mutageneza usmjerena na mjesto protutijela trem-1 za smanjenje viskoziteta |
Country Status (25)
Country | Link |
---|---|
US (3) | US10179814B2 (hr) |
EP (2) | EP3172232B1 (hr) |
JP (2) | JP6738316B2 (hr) |
KR (3) | KR102641268B1 (hr) |
CN (2) | CN113214397A (hr) |
AU (1) | AU2015289054B2 (hr) |
BR (1) | BR112016030947A2 (hr) |
CA (1) | CA2955253C (hr) |
CL (1) | CL2017000113A1 (hr) |
CO (1) | CO2017001397A2 (hr) |
DK (1) | DK3172232T3 (hr) |
EA (1) | EA037844B1 (hr) |
FI (1) | FI3172232T3 (hr) |
HK (1) | HK1232231A1 (hr) |
HR (1) | HRP20240088T1 (hr) |
IL (1) | IL250082B (hr) |
LT (1) | LT3172232T (hr) |
MX (2) | MX2017000484A (hr) |
MY (1) | MY178347A (hr) |
PE (1) | PE20170192A1 (hr) |
PH (1) | PH12017500054A1 (hr) |
RS (1) | RS65136B1 (hr) |
SG (2) | SG11201700250WA (hr) |
TN (1) | TN2017000008A1 (hr) |
WO (1) | WO2016009086A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
CN105431548A (zh) | 2013-03-15 | 2016-03-23 | 生物医学研究机构基金会 | 用于癌转移的诊断、预后和治疗的方法 |
LT3172232T (lt) | 2014-07-17 | 2024-02-12 | Novo Nordisk A/S | Į vietą nukreipta trem-1 antikūnų mutagenezė, skirta klampumui sumažinti |
WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
JP7267280B2 (ja) * | 2017-08-08 | 2023-05-01 | パイオニア イミュノセラピューティクス インコーポレイテッド | Trem1を発現する骨髄細胞を無能化させるための組成物および方法 |
JP2021519594A (ja) | 2018-04-02 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗trem−1抗体およびその使用 |
US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
JP2022540904A (ja) | 2019-07-15 | 2022-09-20 | ブリストル-マイヤーズ スクイブ カンパニー | ヒトtrem-1に対する抗体およびその使用 |
EP4141093A1 (en) | 2020-04-20 | 2023-03-01 | Suntory Holdings Limited | Alcoholic beverage containing steviol glycosides |
CN115586338A (zh) * | 2022-09-20 | 2023-01-10 | 杭州赛基生物科技有限公司 | 用于检测可溶性细胞因子受体的试剂盒及其制备方法 |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2972257B2 (ja) | 1990-01-24 | 1999-11-08 | 株式会社日立製作所 | パケット交換機 |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
IL98764A0 (en) | 1990-07-10 | 1992-07-15 | Smithkline Beecham Corp | Oxamides |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
ES2154637T3 (es) | 1991-05-14 | 2001-04-16 | Univ Connecticut | Aportacion de genes dirigidos que codifican proteinas inmunogenicas. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JPH06510278A (ja) | 1991-06-05 | 1994-11-17 | ユニバーシティ オブ コネチカット | 分泌タンパク質をコードする遺伝子の標的への配達 |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
FR2694851B1 (fr) | 1992-08-12 | 1994-12-23 | Sgs Thomson Microelectronics | Circuit de tirage vers un état déterminé d'une entrée de circuit intégré. |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
KR950703640A (ko) | 1992-10-09 | 1995-09-20 | 가일 케이,나우톤. | 간 보존 세포(liver reserve cells) |
EP0672131B1 (en) | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | A novel cell cycle control protein |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
US6034217A (en) | 1996-09-17 | 2000-03-07 | Wako Pure Chemical Industries, Ltd. | Peptidoglycan recognition proteins and their production |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
US6420526B1 (en) | 1997-03-07 | 2002-07-16 | Human Genome Sciences, Inc. | 186 human secreted proteins |
CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
EP0972029A1 (en) | 1997-03-07 | 2000-01-19 | Human Genome Sciences, Inc. | Human secreted proteins |
US6878687B1 (en) | 1997-03-07 | 2005-04-12 | Human Genome Sciences, Inc. | Protein HMAAD57 |
US20030049618A1 (en) | 1997-03-07 | 2003-03-13 | Ruben Steven M. | 186 human secreted proteins |
US20030175858A1 (en) | 1997-03-07 | 2003-09-18 | Ruben Steven M. | 186 human secreted proteins |
TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ, インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
WO1999018126A1 (fr) | 1997-10-07 | 1999-04-15 | Ono Pharmaceutical Co., Ltd. | POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION |
EP1090118A2 (en) | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
US20030170255A1 (en) | 1999-06-30 | 2003-09-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6858204B2 (en) | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6509448B2 (en) | 1999-06-30 | 2003-01-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20020197669A1 (en) | 2000-12-13 | 2002-12-26 | Bangur Chaitanya S. | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20020172952A1 (en) | 1999-06-30 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US20030134283A1 (en) | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
EP1351702B1 (en) | 2000-12-08 | 2015-03-04 | Bioprovar Corporation | Trem-1 splice variant for use in modifying immune responses |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US20040236092A1 (en) | 2001-07-13 | 2004-11-25 | Roman Dziarski | Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof |
JP2005518782A (ja) | 2001-09-17 | 2005-06-30 | プロテイン デザイン ラブス, インコーポレイテッド | ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法 |
US20030077282A1 (en) | 2001-10-12 | 2003-04-24 | Bigler Michael Eric | Use of bispecific antibodies to regulate immune responses |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
WO2003080667A2 (en) | 2002-03-22 | 2003-10-02 | Bioxell S.P.A. | A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
WO2004020591A2 (en) | 2002-08-29 | 2004-03-11 | Five Prime Therapeutics, Inc. | Methods of use for novel human polypeptides encoded by polynucleotides |
GB0305478D0 (en) | 2003-03-10 | 2003-04-16 | Bioxell Spa | Diagnostic and prognostic compounds and method |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−5γ2結合性ペプチド、その関連組成物およびその使用 |
US20070083333A1 (en) | 2003-11-17 | 2007-04-12 | Vitiello Maria A | Modeling of systemic inflammatory response to infection |
GB0401730D0 (en) | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
EP1735340A2 (en) | 2004-03-17 | 2006-12-27 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
PL1789442T3 (pl) | 2004-09-02 | 2010-02-26 | Lilly Co Eli | Muteiny czynnika wzrostu fibroblastów 21 |
WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006078463A2 (en) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Method for treating cardiovascular disease |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
EP2465511B1 (en) | 2006-10-19 | 2019-05-22 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
CA2675583A1 (en) | 2007-01-16 | 2008-07-24 | Wyeth | Inflammation treatment, detection and monitoring via trem-1 |
PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
KR20100058541A (ko) | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
ES2532116T3 (es) | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Péptidos derivados con A-B-C-D y sus usos terapéuticos |
JP2011508219A (ja) | 2007-12-19 | 2011-03-10 | シンギュレックス・インコーポレイテッド | 単一分子検出走査分析器およびその使用方法 |
JP2011513753A (ja) | 2008-03-05 | 2011-04-28 | シンギュレックス・インコーポレイテッド | 分子の高感度検出の方法および組成物 |
CA2721742A1 (en) | 2008-05-23 | 2009-11-26 | Pronota N.V. | New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof |
RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
ES2445892T3 (es) | 2008-08-25 | 2014-03-05 | Janssen Biotech, Inc. | Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados |
UA105016C2 (uk) | 2008-10-10 | 2014-04-10 | Амген Інк. | Fgf21 мутанти і їх застосування |
WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
CN102361647B (zh) | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
WO2010132370A2 (en) | 2009-05-11 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Soluble tlt-1 for the treatment and diagnosis of sepsis |
WO2010141469A2 (en) | 2009-06-01 | 2010-12-09 | Case Western Reserve University | Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases |
US20120172298A1 (en) | 2009-06-11 | 2012-07-05 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011047097A2 (en) | 2009-10-13 | 2011-04-21 | Sigalov Alexander B | Inhibition of trem receptor signaling with peptide variants |
KR101251023B1 (ko) | 2009-11-05 | 2013-04-03 | 주식회사유한양행 | 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트 |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
KR20130098161A (ko) | 2010-04-30 | 2013-09-04 | 알렉시온 파마슈티칼스, 인코포레이티드 | 인간에서 감소된 면역원성을 갖는 항체 |
JP6014596B2 (ja) | 2010-11-09 | 2016-10-25 | メディミューン,エルエルシー | 均一コンジュゲーションのための抗体足場 |
WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
EP2654792A4 (en) | 2010-12-22 | 2016-05-11 | Abbvie Inc | HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF |
US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
PL3485903T3 (pl) | 2011-09-23 | 2023-06-12 | Mereo Biopharma 5, Inc. | Środki wiążące VEGF/DLL4 i ich zastosowania |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
EP3196214B1 (en) * | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CA2873646C (en) | 2012-05-18 | 2022-04-26 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
MX2015005874A (es) | 2012-11-09 | 2015-09-10 | Pfizer | Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos. |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
LT3172232T (lt) | 2014-07-17 | 2024-02-12 | Novo Nordisk A/S | Į vietą nukreipta trem-1 antikūnų mutagenezė, skirta klampumui sumažinti |
JP2021519594A (ja) * | 2018-04-02 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗trem−1抗体およびその使用 |
-
2015
- 2015-07-17 LT LTEPPCT/EP2015/066501T patent/LT3172232T/lt unknown
- 2015-07-17 AU AU2015289054A patent/AU2015289054B2/en active Active
- 2015-07-17 KR KR1020227038720A patent/KR102641268B1/ko active IP Right Grant
- 2015-07-17 CN CN202110365573.4A patent/CN113214397A/zh active Pending
- 2015-07-17 EP EP15738925.5A patent/EP3172232B1/en active Active
- 2015-07-17 CA CA2955253A patent/CA2955253C/en active Active
- 2015-07-17 FI FIEP15738925.5T patent/FI3172232T3/fi active
- 2015-07-17 SG SG11201700250WA patent/SG11201700250WA/en unknown
- 2015-07-17 BR BR112016030947A patent/BR112016030947A2/pt active Search and Examination
- 2015-07-17 KR KR1020247005919A patent/KR20240029114A/ko not_active Application Discontinuation
- 2015-07-17 DK DK15738925.5T patent/DK3172232T3/da active
- 2015-07-17 WO PCT/EP2015/066501 patent/WO2016009086A1/en active Application Filing
- 2015-07-17 EP EP23211146.8A patent/EP4332119A3/en active Pending
- 2015-07-17 KR KR1020177004011A patent/KR102465120B1/ko active IP Right Grant
- 2015-07-17 SG SG10201913702WA patent/SG10201913702WA/en unknown
- 2015-07-17 US US15/325,865 patent/US10179814B2/en active Active
- 2015-07-17 TN TN2017000008A patent/TN2017000008A1/en unknown
- 2015-07-17 PE PE2017000069A patent/PE20170192A1/es unknown
- 2015-07-17 HR HRP20240088TT patent/HRP20240088T1/hr unknown
- 2015-07-17 JP JP2017502703A patent/JP6738316B2/ja active Active
- 2015-07-17 MX MX2017000484A patent/MX2017000484A/es unknown
- 2015-07-17 MY MYPI2017700169A patent/MY178347A/en unknown
- 2015-07-17 CN CN201580038005.6A patent/CN106536559B/zh active Active
- 2015-07-17 RS RS20240117A patent/RS65136B1/sr unknown
- 2015-07-17 EA EA201790104A patent/EA037844B1/ru not_active IP Right Cessation
-
2017
- 2017-01-09 PH PH12017500054A patent/PH12017500054A1/en unknown
- 2017-01-11 MX MX2020013920A patent/MX2020013920A/es unknown
- 2017-01-12 IL IL250082A patent/IL250082B/en unknown
- 2017-01-16 CL CL2017000113A patent/CL2017000113A1/es unknown
- 2017-02-13 CO CONC2017/0001397A patent/CO2017001397A2/es unknown
- 2017-06-05 HK HK17105554.8A patent/HK1232231A1/zh unknown
-
2018
- 2018-11-28 US US16/203,327 patent/US11072654B2/en active Active
-
2020
- 2020-07-17 JP JP2020122759A patent/JP6995170B2/ja active Active
-
2021
- 2021-07-20 US US17/380,404 patent/US20220010012A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240088T1 (hr) | Mutageneza usmjerena na mjesto protutijela trem-1 za smanjenje viskoziteta | |
HRP20200906T1 (hr) | Il-18 vezujuće molekule | |
EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
HRP20201113T1 (hr) | Vežući proteini protiv lag-3 | |
HRP20211221T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
EA201791422A1 (ru) | Фармацевтические продукты и устойчивые жидкие композиции антител к il-17 | |
MX2016004907A (es) | Analogos del glucagon. | |
AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
PH12016500675A1 (en) | Acylated glucagon analogues | |
JP2016509009A5 (hr) | ||
WO2016144803A3 (en) | Antibody therapeutics that bind tim3 | |
EA201590294A1 (ru) | Аналоги глюкагона | |
HRP20140915T1 (hr) | Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo | |
JOP20140049B1 (ar) | أجسام مضادة ترتبط بـ il-23 | |
MX2017012864A (es) | Analogo acilado del glucagon. | |
TN2017000352A1 (en) | Antibodies to tau and uses thereof | |
BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
CL2011002744A1 (es) | Anticuerpo anti il-17f monoclonal; composicion farmaceutica; uso de dicho anticuerpo para artritis reumatoide, enfermedad de crohn, psoriasis, esclerosis multiple, enfermedad pulmonar obstructiva cronica o asma en un sujeto. | |
CL2017000703A1 (es) | Anticuerpos anti-il-25 y usos de los mismos | |
Mintz et al. | Protein scaffolds | |
BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
HRP20141110T1 (hr) | Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo | |
BR112017004590A2 (pt) | métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l | |
WO2017081218A3 (en) | Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3 |